ICU Medical Inc. (NASDAQ:ICUI) – Roth Capital decreased their Q4 2017 earnings estimates for ICU Medical in a report issued on Thursday. Roth Capital analyst C. Lewis now anticipates that the firm will post earnings per share of $1.05 for the quarter, down from their prior forecast of $1.10.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Monday, August 8th. The company reported $1.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.10. ICU Medical had a return on equity of 10.33% and a net margin of 14.94%. The company earned $96.70 million during the quarter, compared to the consensus estimate of $89.66 million. During the same period in the previous year, the company posted $0.97 earnings per share. ICU Medical’s revenue for the quarter was up 15.4% on a year-over-year basis.
Other research analysts also recently issued research reports about the company. Zacks Investment Research upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $140.00 price objective on the stock in a report on Friday, August 12th. Piper Jaffray Cos. reiterated a “neutral” rating and issued a $119.00 price objective (up previously from $115.00) on shares of ICU Medical in a report on Thursday, August 11th.
Shares of ICU Medical (NASDAQ:ICUI) traded up 3.44% on Friday, reaching $149.65. The company’s stock had a trading volume of 482,277 shares. The stock has a 50-day moving average price of $126.14 and a 200-day moving average price of $112.44. ICU Medical has a 1-year low of $85.56 and a 1-year high of $150.37. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of 44.57 and a beta of 0.37.
Several hedge funds and other institutional investors have recently made changes to their positions in ICUI. Eqis Capital Management Inc. increased its position in shares of ICU Medical by 86.3% in the third quarter. Eqis Capital Management Inc. now owns 4,675 shares of the company’s stock valued at $591,000 after buying an additional 2,166 shares during the period. Mason Street Advisors LLC bought a new position in shares of ICU Medical during the second quarter valued at $319,000. Royal Bank of Canada increased its position in shares of ICU Medical by 57.2% in the second quarter. Royal Bank of Canada now owns 207,226 shares of the company’s stock valued at $23,365,000 after buying an additional 75,396 shares during the period. Schwab Charles Investment Management Inc. increased its position in shares of ICU Medical by 4.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 48,889 shares of the company’s stock valued at $5,513,000 after buying an additional 2,004 shares during the period. Finally, Stifel Financial Corp increased its position in shares of ICU Medical by 10.9% in the second quarter. Stifel Financial Corp now owns 67,649 shares of the company’s stock valued at $7,627,000 after buying an additional 6,656 shares during the period. Institutional investors own 89.50% of the company’s stock.
In other ICU Medical news, VP Steven Riggs sold 44,739 shares of ICU Medical stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $121.78, for a total value of $5,448,315.42. Following the transaction, the vice president now directly owns 675 shares in the company, valued at approximately $82,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard Md Sherman sold 1,500 shares of ICU Medical stock in a transaction that occurred on Thursday, October 6th. The shares were sold at an average price of $140.60, for a total value of $210,900.00. Following the completion of the transaction, the director now owns 70,699 shares in the company, valued at $9,940,279.40. The disclosure for this sale can be found here. Corporate insiders own 15.90% of the company’s stock.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.